The Global Cardiac Resynchronization Therapy (CRT) Market, valued at USD 7.94 Billion in 2025, is projected to exhibit a CAGR of 6.6%, reaching USD 12.42 Billion by 2032.
The market growth is primarily driven by the rising prevalence of heart failure and other cardiovascular disorders, coupled with the increasing adoption of advanced cardiac rhythm management devices to improve patient outcomes. Advancements in CRT devices, such as the development of leadless, MRI-compatible, and wireless systems, along with enhanced device longevity and remote monitoring capabilities, are fueling the market expansion.
Additionally, growing geriatric population prone to cardiovascular diseases, supportive reimbursement policies, and expanding access to healthcare in emerging economies are contributing to the rising demand for CRT devices. Increasing clinical evidence demonstrating the efficacy of CRT in reducing hospitalizations and improving survival rates, along with strategic investments by key market players in product innovation and commercialization, is expected to create significant opportunities for the market growth over the forecast period.
Market Takeaways
Global Cardiac Resynchronization Therapy (CRT) Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/cardiac-resynchronization-therapy-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 7.94 Billion |
|
Estimated Value by 2032 |
USD 12.42 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 6.6% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global cardiac resynchronization therapy (CRT) market is witnessing steady growth, primarily driven by the rising prevalence of heart failure and other cardiovascular diseases, coupled with the growing adoption of advanced cardiac rhythm management devices. The demand for CRT is further fueled by the proven benefits of these therapies in improving left ventricular function, reducing hospitalizations, and enhancing survival rates in patients with moderate to severe heart failure.
A key growth driver is the increasing adoption of CRT-Defibrillators (CRT-D), which offer dual benefits of cardiac pacing and defibrillation, providing better outcomes for patients at risk of sudden cardiac death. Technological advancements such as MRI-compatible devices, leadless CRT systems, wireless communication features, and improved battery life are enhancing device performance, making CRT therapies more effective and accessible. The integration of remote monitoring capabilities further supports timely intervention and ongoing patient management, strengthening adoption across healthcare facilities.
The market is also supported by the growing geriatric population, which faces a higher risk of chronic heart failure, as well as supportive reimbursement policies in developed countries and expanding access to advanced healthcare infrastructure in emerging economies. Rising awareness about the early diagnosis and clinical efficacy of CRT in improving patient quality of life is further contributing to the market expansion.
However, the market faces challenges such as the high cost of CRT devices and implantation procedures, which can limit accessibility in low- and middle-income countries. Additionally, risks associated with device implantation, such as infections, lead displacement, and the need for re-intervention, pose hurdles to broader adoption. Despite these challenges, ongoing innovations in device technology, expanding healthcare coverage in emerging markets, and the growing integration of artificial intelligence (AI) for personalized therapy optimization are expected to sustain robust growth in the CRT market over the forecast period.
Market Trends
Manufacturers are increasingly focusing on developing leadless and smaller-sized CRT systems that simplify implantation procedures, reduce risks of lead-related complications, and improve patient comfort, driving higher adoption in both developed and emerging markets.
In April 2025, EBR Systems, Inc. received the USFDA approval of WiSE System, which marks a significant leap forward in the treatment of heart failure. Unlike conventional CRT, the WiSE System is the first and only to deliver leadless left ventricular endocardial pacing (LVEP), which closely aligns with the heart's natural conduction pathway. The endocardial approach represents a more physiological method of resynchronization and allows electrophysiologists to treat patients who are not able to receive lead-based devices. This advancement offers a pioneering treatment option for patients who have limited access to conventional CRT therapies.
The incorporation of connected technologies, such as wireless remote monitoring, cloud-based data sharing, and AI-powered analytics, is enhancing the ability of healthcare providers to track device performance, optimize therapy delivery, and predict adverse events, improving overall patient outcomes.
In October 2024, the National Library of Medicine featured a study titled “Smartphone App-Based Remote Monitoring Challenges in Patients with CRT-Defibrillators.” The study compared patients with CRT-D devices enabled for smartphone app-based remote monitoring to those using traditional follow-up methods. It evaluated connectivity rates, adherence to automatic follow-ups, and the prevalence of alert-based events, highlighting how mobile technologies are increasingly being leveraged to improve remote device management for CRT-D patients.
Market Opportunities
Rapid improvements in cardiac care facilities, increasing healthcare spending, and government initiatives aimed at strengthening cardiovascular disease management across regions such as Asia-Pacific, Latin America, and the Middle East are creating substantial growth opportunities for the adoption of CRT devices. Emerging markets are witnessing a surge in specialized cardiac centers, increased availability of trained cardiologists, and broader access to advanced medical technologies, which together are facilitating higher adoption rates of CRT therapies.
Additionally, supportive health policies, insurance coverage expansion, and public–private partnerships in healthcare infrastructure are further enabling patients to access these life-saving treatments. Rising awareness of heart failure management and the benefits of advanced cardiac devices in improving patient outcomes are also contributing to the expanding demand for CRT solutions in these regions.
Leveraging artificial intelligence, cloud analytics, and wearable-connected CRT devices to predict heart failure events, tailor therapy delivery, and enable proactive patient care opens new avenues for product differentiation and value-based healthcare partnerships.
An article published by Wolters Kluwer in October 2024, titled “Harnessing Artificial Intelligence in Cardiology: Advancements in Diagnosis, Treatment, and Patient Care,” explored the role of AI in personalizing cardiology treatments. By analyzing individual patient data, AI algorithms can predict responses to specific medications, enabling the creation of customized treatment plans that improve efficacy and reduce the risk of adverse effects. This advancement is particularly significant for cardiac resynchronization therapy (CRT), where personalized therapy is critical for achieving optimal patient outcomes.
Analyst View
Key Development
In July 2025, Abbott's Gallant line of CRT-D devices received FDA approval. These devices feature Bluetooth connectivity and continuous remote monitoring capabilities, enhancing patient management and therapy adherence.
In May 2023, BIOTRONIK received CE approval for its Amvia Sky and Amvia Edge CRT devices, the world's first approved for left bundle branch pacing. This innovation offers a new approach to cardiac resynchronization therapy.
Competitive Landscape
Cardiac Resynchronization Therapy Market Segmentation
Regional Insights
Related Reports :